Venture Capital

  • Posted on 1/15/21

    Own Up Raises $12M

    Own Up, a Boston, MA-based mortgage marketplace, raised $12m in funding. The round was led by Brand Foundry Ventures with participation from Link Ventures, Listen Ventures, . . .

  • Posted on 1/15/21

    Battery Ventures Join $85M Series C For Harness

    Harness, a San Francisco, CA-based platform for software delivery, raised $115m in financing, reaching a valuation of $1.7 billion in three years.

  • Posted on 1/15/21

    airSlate Raises $40M in Funding

    airSlate, a Boston, MA-based provider of no-code business automation solutions, raised $40m in funding

  • Posted on 1/14/21

    Home Diversification Corp Announces $11M Private Funding Round

    Home Diversification Corp, a startup Fintech financial product provider and creator of the home diversification concept

  • Posted on 1/13/21

    Capchase Closes $60M Funding Led By i80 Group

    Capchase, a Boston-based provider of non-dilutive capital for Software-as-a-Service (SaaS) companies, has today announced $60M in additional funding,

  • Posted on 1/13/21

    Micatu Secures $10 Million Investment from WAVE Equity Partners

    HORSEHEADS, N.Y.--(BUSINESS WIRE)--Micatu, Incorporated, a leader in optical sensing solutions,today announced a $10 million growth investment led by WAVE Equity Partners, LLC. The financing will support . . .

  • Posted on 1/13/21

    Slim.ai Raises $6.6M in Seed Funding

    Slim.ai, a Boxborough, Mass.-based cloud-based DevOps automation platform built specifically for software developers, raised $6.6m in seed funding.

  • Posted on 1/12/21

    Jellyfish Raises $31.5 Million Series B Funding

    Jellyfish, the pioneer Engineering Management Platform that helps engineering leaders align engineering work with strategic business objectives, has raised $31.5 million in a Series B round

  • Posted on 1/12/21

    Valo Raises $190 Million in Series B

    Valo Health LLC (Valo), the technology company working to transform the drug discovery and development process and accelerate the creation of life-changing drugs, closed a $190 . . .

  • Posted on 1/12/21

    Radian Generation Closes Investment from 424 Capital

    Radian Generation LLC (Radian) announced today it closed an investment from 424 Capital (424) during the last week of 2020. The investment makes 424 Capital the . . .

  • Posted on 1/12/21

    Boston Metal Raises $50 Million Series B

    BOSTON--(BUSINESS WIRE)--Boston Metal today announced it raised $50 million in Series B funding, positioning the company to accelerate industrial-scale deployments of its molten oxide electrolysis (MOE) . . .

  • Posted on 1/12/21

    Sensei Biotherapeutics Announces $30 Million Financing

    BOSTON & ROCKVILLE, Md.--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc., a clinical-stage cancer immunotherapy company, today announced the successful closing of a $30 million Series B financing. The financing . . .

  • Posted on 1/11/21

    Atalanta Therapeutics Raises $110M in Series A Funding

    Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative

  • Posted on 1/11/21

    EQRx Closes $500 Million Series B

    EQRx, a company committed to developing and delivering important new medicines at lower prices, today announced that it has raised $500 million in Series B financing.

  • Posted on 1/8/21

    Carrum Health Raises $40M in Series A Funding

    Carrum Health, a San Francisco, CA-based digital health company connecting employers and employees to Centers of Excellence (COEs) through a technology-powered platform, closed a $40m Series . . .

  • Posted on 1/8/21

    MANA Therapeutics Launches with $35 Million Series A Financing

    WALTHAM, Mass.--(BUSINESS WIRE)--MANA Therapeutics, a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, today announced a $35 million Series A financing. . . .

  • Posted on 1/8/21

    Affinivax Announces $226 Million Series C Financing

    Affinivax, Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS platform, today announced the closing of a . . .

  • Posted on 1/7/21

    Bessemer Leads $23M Series B for Aspen RxHealth

    Aspen RxHealth, whose first of its kind clinical pharmacy model developed by pharmacists for pharmacists delivers value for health plans and risk-bearing providers

  • Posted on 1/7/21

    IsoPlexis Announces $135 Million Series D Led by Perceptive Advisors

    IsoPlexis, the leader in single-cell functional proteomics, today announced a $135 million Series D financing comprised of $85 million in equity securities and a $50 million . . .

  • Posted on 1/7/21

    Werewolf Therapeutics Completes $72 Million Series B Financing

    Werewolf Therapeutics, Inc., an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments, today announced the completion of its $72 million Series B financing.

  • Posted on 1/7/21

    Kira Pharmaceuticals Closes $53.5 Million Series B+ Financing

    Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the first closing of an oversubscribed $53.5 . . .

  • Posted on 1/7/21

    LifeMine Therapeutics Raises $50 Million Series B

    LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced a $50 million

  • Posted on 1/7/21

    Scorpion Therapeutics Raises $162M In Series B

    Scorpion Therapeutics, Inc., a next-generation precision oncology company, today announced the closing of an oversubscribed Series B financing, which raised $162 million.

  • Posted on 1/7/21

    Abcuro Raises $42 Million in Series A-1

    Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells

  • Posted on 1/6/21

    Adeptrix Closes Series A

    Adeptrix Corp, the developer of advanced bioanalytical tools based on its proprietary BAMS™ (Bead Assisted Mass Spectrometry)